Reilly Financial Advisors’s Celldex Therapeutics CLDX Stock Holding History

Reilly Financial Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7	Closed	-$2K	–	1207
2015 Q4	$2K	Buy	+7	New	+$1.53K	﹤0.01%	1063

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Reilly Financial Advisors's CLDX Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 7 shares.

Reilly Financial Advisors first reported a position in CLDX in Q4 2014 and held it in 7 quarters. The position peaked at $10K in Q2 2015. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

Reilly Financial Advisors reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
Reilly Financial Advisors sold 7 Celldex Therapeutics shares in Q1 2017.
Reilly Financial Advisors first reported a position in Celldex Therapeutics in Q4 2014 and held it in 7 quarters.
Reilly Financial Advisors's Celldex Therapeutics position peaked at $10K in Q2 2015.
134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.